{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:39:10Z","timestamp":1793219950445,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10637-018-0660-3","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T05:44:19Z","timestamp":1536212659000},"page":"1085-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study"],"prefix":"10.1007","volume":"36","author":[{"given":"Pedro C.","family":"Barata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Mendiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"660_CR1","unstructured":"National Cancer Institute (2017) Surveillance Epidemiology, and end results program. Prostate Cancer. Retrieved from http:\/\/www.seer.cancer.gov. Accessed August 2018"},{"key":"660_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"660_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. Jama 294:238\u2013244","journal-title":"Jama"},{"key":"660_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ucl.2012.07.011","volume":"39","author":"HH Cheng","year":"2012","unstructured":"Cheng HH, Lin DW, Yu EY (2012) Advanced clinical states in prostate cancer. Urol Clin North Am 39:561\u2013571","journal-title":"Urol Clin North Am"},{"key":"660_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"660_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O\u2019Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR (2017) Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med 377:338\u2013351","journal-title":"N Engl J Med"},{"key":"660_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AWS, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MKB (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163\u20131177","journal-title":"Lancet"},{"key":"660_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, de Porre P, Kheoh T, Park YC, Todd MB, Chi KN (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer. N Engl J Med 377:352\u2013360","journal-title":"N Engl J Med"},{"key":"660_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2265.1986.tb01662.x","volume":"24","author":"R De Coster","year":"1986","unstructured":"De Coster R, Caers I, Coene MC et al (1986) Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol 24:657\u2013664","journal-title":"Clin Endocrinol"},{"key":"660_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1755::AID-CNCR9>3.0.CO;2-D","volume":"80","author":"EJ Small","year":"1997","unstructured":"Small EJ, Baron A, Bok R (1997) Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755\u20131759","journal-title":"Cancer"},{"key":"660_CR11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","volume":"157","author":"EJ Small","year":"1997","unstructured":"Small EJ, Baron AD, Fippin L, Apodaca D (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204\u20131207","journal-title":"J Urol"},{"key":"660_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","volume":"168","author":"KA Harris","year":"2002","unstructured":"Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ (2002) Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168:542\u2013545","journal-title":"J Urol"},{"key":"660_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"EJ Small","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025\u20131033","journal-title":"J Clin Oncol"},{"key":"660_CR14","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650\u20134657","journal-title":"Clin Cancer Res"},{"key":"660_CR15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc R, Hideshima T, Catley LP et al (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787\u20131790","journal-title":"Blood"},{"key":"660_CR16","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1158\/1078-0432.CCR-10-1928","volume":"16","author":"D Keizman","year":"2010","unstructured":"Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M (2010) Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I\/II double-blinded, randomized study. Clin Cancer Res 16:5269\u20135276","journal-title":"Clin Cancer Res"},{"key":"660_CR17","doi-asserted-by":"publisher","first-page":"33.e11\u201337","DOI":"10.1016\/j.urolonc.2012.12.004","volume":"32","author":"JA Garcia","year":"2014","unstructured":"Garcia JA, Elson P, Tyler A et al (2014) Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol 32:33.e11\u201337","journal-title":"Urol Oncol"},{"key":"660_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bju.13412","volume":"118","author":"RA Madan","year":"2016","unstructured":"Madan RA, Karzai FH, Ning Y-M, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Chen C, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL (2016) Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU Int 118:590\u2013597","journal-title":"BJU Int"},{"key":"660_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clgc.2013.09.001","volume":"12","author":"C Nabhan","year":"2014","unstructured":"Nabhan C, Patel A, Villines D et al (2014) Lenalidomide Monotherapy in chemotherapy-naive, castration-resistant prostate Cancer patients: final results of a phase II study. Clin Genitourin Cancer 12:27\u201332","journal-title":"Clin Genitourin Cancer"},{"key":"660_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10585-015-9696-3","volume":"32","author":"J Wang","year":"2015","unstructured":"Wang J, McGuire TR, Britton HC et al (2015) Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clin Exp Metastasis 32:111\u2013124","journal-title":"Clin Exp Metastasis"},{"key":"660_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate Cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"660_CR22","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/cncr.26582","volume":"118","author":"JA Garcia","year":"2012","unstructured":"Garcia JA, Rini BI (2012) Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 118:2583\u20132593","journal-title":"Cancer"},{"key":"660_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/01.ju.0000147013.09157.8e","volume":"173","author":"WD Figg","year":"2005","unstructured":"Figg WD, Liu Y, Arlen P et al (2005) A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 173:790\u2013796","journal-title":"J Urol"},{"key":"660_CR24","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461\u20133467","journal-title":"J Clin Oncol"},{"key":"660_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ (2016) Trial design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials working group 3. J Clin Oncol 34:1402\u20131418","journal-title":"J Clin Oncol"},{"key":"660_CR26","doi-asserted-by":"crossref","first-page":"53053","DOI":"10.18632\/oncotarget.18085","volume":"8","author":"F Costa","year":"2017","unstructured":"Costa F, Vescovini R, Bolzoni M et al (2017) Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget 8:53053\u201353067","journal-title":"Oncotarget"},{"key":"660_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033\u20131045","journal-title":"Cancer Immunol Immunother"},{"key":"660_CR28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V116.21.492.492","volume":"116","author":"K Luptakova","year":"2010","unstructured":"Luptakova K, Glotzbecker B, Mills H et al (2010) Lenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma\/dendritic cell fusion vaccine in vitro. Blood 116:492\u2013492","journal-title":"Blood"},{"key":"660_CR29","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257\u2013e267","journal-title":"Lancet Oncol"},{"key":"660_CR30","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube A, Klein-Gonz\u00e1lez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M (2011) Dendritic cell based tumor vaccination in prostate and renal cell Cancer: a systematic review and meta-analysis. PLoS One 6:e18801","journal-title":"PLoS One"},{"key":"660_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"660_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, de Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152\u2013160","journal-title":"Lancet Oncol"},{"issue":"15","key":"660_CR33","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"Matthew R. Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"New England Journal of Medicine"},{"issue":"6_suppl","key":"660_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/JCO.2018.36.6_suppl.3","volume":"36","author":"Maha Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore ND, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN (2018). PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol 2018 36(6). https:\/\/doi.org\/10.1200\/JCO.2018.36.6_suppl.3","journal-title":"Journal of Clinical Oncology"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0660-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:27:05Z","timestamp":1678559225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0660-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0660-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Pedro Barata declares that he has no conflicts of interest. Matthew Cooney declares that he has no conflicts of interest. Prateek Mendiratta declares that he has no conflicts of interest. Allison Tyler declares that she has no conflicts of interest. Robert Dreicer declares that he has no conflicts of interest. Jorge A. Garcia declares that he has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent prior to study entry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}